We are live on ! Find out more
LPC

Lion Point Capital Portfolio holdings

AUM $16.7M
1-Year Est. Return 119.35%
This Fund
S&P 500
This Quarter Est. Return
+34.99%
1 Year Est. Return
+119.35%
3 Year Est. Return
+204.43%
5 Year Est. Return
+220.32%
10 Year Est. Return
+1,396.08%
AUM
$17.6M
AUM Growth
+$2.87M
Cap. Flow
+$1.84M
Cap. Flow %
10.47%
Top 10 Hldgs %
58.11%
Holding
27
New
8
Increased
3
Reduced
8
Closed
–

Top Buys

Rank Stock Value
1
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$3.52M
2
RPRX icon
Royalty Pharma
RPRX
+$775K
3
JSPR icon
Jasper Therapeutics
JSPR
+$764K
4
KURA icon
Kura Oncology
KURA
+$328K
5
DAWN
Day One Biopharmaceuticals
DAWN
+$289K

Top Sells

Rank Stock Value
1
ARDX icon
Ardelyx
ARDX
+$938K
2
MLYS icon
Mineralys Therapeutics
MLYS
+$865K
3
KNSA icon
Kiniksa Pharmaceuticals
KNSA
+$731K
4
FENC icon
Fennec Pharmaceuticals
FENC
+$629K
5
BBIO icon
BridgeBio Pharma
BBIO
+$619K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HUMA icon
26
Humacyte
HUMA
$176M
$145K 0.83%
83,500
– –
SPRB
27
Spruce Biosciences
SPRB
$118M
$8.95K 0.05%
+1,000
New +$8.85K
1
2

Similar funds

PA
PPM America Chicago, Illinois $16.6M AUM 31.99% 1-Year Est. Return
SR
Swiss Re Zurich, Switzerland $16.4M AUM
SCTC
Samsung C&T Corporation Seoul, South Korea $17.2M AUM 23.45% 1-Year Est. Return
SRA
Summit Rock Advisors New York $16M AUM
CP
Covalent Partners Concord, Massachusetts $17.6M AUM 2.91% 1-Year Est. Return
B
BP London, United Kingdom $17.7M AUM 12.34% 1-Year Est. Return
BCPE
Bain Capital Public Equity Boston, Massachusetts $18M AUM 35.19% 1-Year Est. Return
AE
Axon Enterprise Scottsdale, Arizona $18.1M AUM 29.08% 1-Year Est. Return

Lion Point Capital's Q3 2025 Portfolio in Review

As of Q3 2025, Lion Point Capital held 27 positions worth $17.6M, up 20% from $14.7M the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Lion Point Capital deployed $1.84M of net new capital in Q3 2025, opening 8 new positions and adding to 3 existing holdings. Its largest new stake was MoonLake Immunotherapeutics: 67,500 shares worth $484K.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Ardelyx, an estimated $938K trimmed.

  • Lion Point Capital's largest Q3 2025 buy was MoonLake Immunotherapeutics: 67,500 shares worth $484K.
  • Lion Point Capital added most to Jasper Therapeutics in Q3 2025, an estimated $764K increase.
  • Lion Point Capital's biggest Q3 2025 reduction was Ardelyx, cutting an estimated $938K.
  • Lion Point Capital's ten largest holdings make up 58% of its $17.6M portfolio in Q3 2025.
  • Lion Point Capital opened 8 new positions and closed 0 in Q3 2025.
  • Lion Point Capital's portfolio value rose 20% quarter-over-quarter to $17.6M.

Based on Lion Point Capital's 13F filing for Q3 2025, filed 14 Nov 2025.